Table 3 Cardiac toxicities.
From: Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Standard CMT | PET-2-guided treatment | Total | ||||
|---|---|---|---|---|---|---|
Female patients | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) |
LVEF (baseline), all available data | 200 | 64.6% (8.3) | 199 | 64.8% (7.8) | 399 | 64.7% (8.0) |
LVEF (baseline), only patients with follow-up data | 37 | 66.7% (9.2) | 35 | 64.4% (8.9) | 72 | 65.6% (9.1) |
LVEF (5-year follow-up) | 37 | 63.4% (7.8) | 35 | 65.1% (8.6) | 72 | 64.2% (8.2) |
Male patients | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) |
LVEF (baseline), all available data | 279 | 63.8% (7.4) | 264 | 63.6% (6.7) | 543 | 63.7% (7.1) |
LVEF (baseline), only patients with follow-up data | 46 | 63.0% (9.7) | 36 | 63.9% (5.2) | 82 | 63.4% (8.0) |
LVEF (5-year follow-up) | 46 | 60.3% (8.7) | 36 | 60.1% (6.5) | 82 | 60.2% (7.7) |
